Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 111, Issue 12, Pages 1682-1690Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ajg.2016.441
Keywords
-
Categories
Funding
- Medical Research Council [G0701898]
- Crohn's and Colitis UK [M16-1]
- Edinburgh GI Trustees
- EU FP-7 grants [305676-2, 305479-2]
- Chief Scientist Office [CZB/4/540, ETM/137, ETM/75] Funding Source: researchfish
- Crohn's and Colitis UK [M16-1] Funding Source: researchfish
- Medical Research Council [1202121, G0800759, G0600329, G0701898] Funding Source: researchfish
- MRC [G0701898, G0600329, G0800759] Funding Source: UKRI
Ask authors/readers for more resources
The completion of the human genome project in 2003 represented a major scientific landmark, ushering in a new era with hopes and expectations of fresh insights into disease mechanisms and treatments. In inflammatory bowel disease (IBD), many important discoveries soon followed, notably the identification of >200 genetic susceptibility loci and characterization of the gut microbiome. As big data, driven by advances in technology, becomes increasingly available and affordable, individuals with IBD and clinicians alike yearn for tangible outcomes from the promise of precision medicine-precise diagnosis, monitoring, and treatment. Here, we provide a commentary on the prospects and challenges of precision medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will have the most impact: (1) disease susceptibility, activity, and behavior; (2) prediction of drug response and adverse effects; and (3) identification of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available